Peroxisome proliferator-activated receptor and retinoic x receptor in alcoholic liver disease.
- Authors
- Mello, Tommaso; Polvani, Simone; Galli, Andrea
- Year
- 2009
- Journal
- PPAR research
- PMID
- 19756185
- DOI
- 10.1155/2009/748174
- PMCID
- PMC2743826
A growing number of new studies demonstrate that nuclear receptors are involved in the development of alcoholic liver disease (ALD). Ethanol metabolism and RXR/PPAR functions are tightly interconnected in the liver. Several ethanol metabolizing enzymes are potently regulated by RXR and PPARalpha after alcohol consumption. The increased ethanol metabolism, in turn, leads to alteration of the redox balance of the cells and impairment of RXR/PPAR functions by direct and indirect effects of acetaldehyde, resulting in deranged lipid metabolism, oxidative stress, and release of proinflammatory cytokines. The use of animal models played a crucial role in understanding the molecular mechanisms of ALD. In this paper we summarize the reciprocal interactions between ethanol metabolism and RXR/PPAR functions. In conclusion, RXR and PPAR play a central role in the onset and perpetuation of the mechanisms underling all steps of the clinical progression in ALD.
No figures extracted from this document.
| Name | Type |
|---|---|
| 4-methylpirazole local | drug |
| 9-cis retinoic acid local | drug |
| 9-cis-retinoic acid local | drug |
| ABL1 local | gene |
| ACADM local | gene |
| acetaldehyde | drug |
| acetic acid | drug |
| acetyl-CoA | drug |
| ACOX1 local | gene |
| Activation of stellate cells local | phenotype |
| acyl-CoA oxidase local | gene |
| Acyl-CoA oxidase local | gene |
| Acyl-CoA synthetase local | gene |
| ADH | gene |
| ADH1A | gene |
| ADH2 | gene |
| ADH3 local | gene |
| adipogenesis | phenotype |
| adiponectin | drug |
| adipose tissue | phenotype |
| alcohol | phenotype |
| Alcohol-fed animals local | cohort |
| alcoholic liver disease | phenotype |
| Alcoholic liver steatosis local | phenotype |
| alcohol-induced steatohepatitis local | phenotype |
| alcoholism | phenotype |
| alcohol metabolism | phenotype |
| Alcohol toxicity | phenotype |
| ALDH1 local | gene |
| ALDH2 | gene |
| Altered inflammatory response in epidermis local | phenotype |
| alternative activation | phenotype |
| AMPK | gene |
| angiogenesis | phenotype |
| Animal model of sepsis local | cohort |
| APOA1 local | gene |
| APOC3 | gene |
| apoptosis | phenotype |
| Bcl2 | gene |
| Bcl-XL local | gene |
| breast cancer | phenotype |
| C57BL/6J | cohort |
| CAR | gene |
| Cardiac Muscle local | cohort |
| carnitine palmitoyl transferase-1 local | gene |
| Carnitine palmitoyl transferase-1 local | gene |
| Cd14 | gene |
| central nervous system | anatomy |
| Cholesterol efflux | phenotype |
| clofibrate local | drug |
| collagen deposition local | phenotype |
| corpus callosum | anatomy |
| CRBP1 local | gene |
| C-reactive protein | phenotype |
| cyanamide | drug |
| CYP2A6 | gene |
| CYP2B local | gene |
| CYP2E1 | gene |
| CYP3A local | gene |
| Cyp4a | gene |
| CYP4A1 local | gene |
| Cytochrome P450 enzymes | gene |
| cytosolic enzyme local | drug |
| Defective myelination of corpus callosum local | phenotype |
| EHHADH local | gene |
| ERK1/2 local | drug |
| ERK1/2 | gene |
| ethanol consumption | phenotype |
| Ethanol-fed mice | cohort |
| ethanol-fed rats local | cohort |
| Ethanol-fed rats local | cohort |
| Ethanol-fed rodents local | cohort |
| ethanol-induced damage local | phenotype |
| ethanol induced liver damage local | phenotype |
| FABP1 | gene |
| fatty acids | drug |
| Fatty acid β-oxidation local | phenotype |
| fatty liver | phenotype |
| female mice | cohort |
| fibrinogen-α local | drug |
| fibrinogen-β local | drug |
| food intake | phenotype |
| Gastrointestinal Tract local | cohort |
| glucose | drug |
| Glucose-Lipid Homeostasis local | phenotype |
| glucose metabolism | phenotype |
| glutathione | drug |
| GSH | drug |
| GSTA2 local | gene |
| GST alpha family local | gene |
| GST chi family local | gene |
| GST kappa family local | gene |
| GST microsomal family local | gene |
| GST mu class local | gene |
| GST mu family local | gene |
| GST pi class local | gene |
| GST pi family local | gene |
| GSTs local | gene |
| GST sigma family local | gene |
| GST theta family local | gene |
| GST zeta family local | gene |
| H4IIE hepatocytes local | cohort |
| HDL cholesterol | phenotype |
| Heavy ethanol consumption local | phenotype |
| hepatic injury local | phenotype |
| hepatic steatosis | phenotype |
| Hepatic triacylglycerol accumulation local | phenotype |
| hepatocyte RXRα-deficient mice local | cohort |
| Hepatocyte RXRα-deficient mice local | cohort |
| higher serum cholesterol local | phenotype |
| higher serum leptin levels local | phenotype |
| high-fat diet | drug |
| humans | cohort |
| hydrogen peroxide | drug |
| hypoglycemia | phenotype |
| IGF-1 | drug |
| IL-1 | drug |
| IL-1 local | gene |
| IL-6 | drug |
| IL6 | gene |
| improved glucose tolerance local | phenotype |
| Increased cancer risk local | phenotype |
| Increased intestinal permeability local | phenotype |
| inflammation | phenotype |
| Inflammatory Activity of Macrophages local | phenotype |
| inflammatory profile local | phenotype |
| insulin | drug |
| insulin sensitivity | phenotype |
| Insulin signalling local | phenotype |
| Intestinal permeability local | phenotype |
| Iron | drug |
| Kupffer cells local | drug |
| L165,041 local | drug |
| larger fat mass local | phenotype |
| leptin | drug |
| L-fatty acid binding protein local | gene |
| lipid metabolism | phenotype |
| lipid peroxidation | phenotype |
| lipid peroxide local | drug |
| lipopolysaccharide | drug |
| Lipotoxicity local | phenotype |
| liver | anatomy |
| Liver cirrhosis | phenotype |
| liver disease | phenotype |
| liver injury | phenotype |
| liver regeneration local | phenotype |
| Liver regeneration local | phenotype |
| LPS | drug |
| LRAT local | gene |
| LTB4 | drug |
| LXRA local | gene |
| Macrophages local | cohort |
| male mice | cohort |
| malonyl Co-A local | drug |
| MAPK | gene |
| MAPK8 | gene |
| MCP-1 | drug |
| Me1 | gene |
| medium chain acyl CoA dehydrogenase local | gene |
| mice | cohort |
| microsomal enzyme local | drug |
| mitochondrial dysfunction | phenotype |
| mouse model of obesity-induced insulin resistance local | cohort |
| mutant mice | cohort |
| NAD+ | drug |
| NADH | drug |
| NADPH | drug |
| NADPH oxidase | drug |
| NADPH oxidase local | gene |
| necroinflammatory injury local | phenotype |
| Neurological impairment in fetus local | phenotype |
| NFKB1 | gene |
| NF-κB | gene |
| nitric oxide | drug |
| nonalcoholic liver injury local | phenotype |
| NOS2 | gene |
| NR1I2 local | gene |
| null mice local | cohort |
| obesity | phenotype |
| obesity-induced insulin resistance local | phenotype |
| oxidative stress | phenotype |
| p38 local | drug |
| PDGF | drug |
| pioglitazone | drug |
| PPAR | gene |
| PPARA | gene |
| PPARA activation local | phenotype |
| PPARA null mice local | cohort |
| PPARD | gene |
| PPARG | gene |
| PPARGC1A | gene |
| PPAR KO mouse model local | cohort |
| PPARα | gene |
| PPARα−/− mice | cohort |
| PPARβ/δ | gene |
| PPARβ/δ agonist local | drug |
| PPARγ | gene |
| PPARγ +/- mice local | cohort |
| PRKCD | gene |
| pro-fibrogenic response local | phenotype |
| pro-inflammatory cytokines | phenotype |
| RARA | gene |
| RARB local | gene |
| RARG local | gene |
| rats | cohort |
| Reduced adipose tissue local | phenotype |
| Reduced GSH levels local | phenotype |
| Resveratrol local | drug |
| retinoic acid | drug |
| rodents | cohort |
| ROS | drug |
| rosiglitazone | drug |
| RXR | gene |
| RXRA null mice local | cohort |
| RXR deficient mice local | cohort |
| RXR KO mice local | cohort |
| RXR KO mouse model local | cohort |
| RXR null mice local | cohort |
| RXRα local | gene |
| RXRα deficient mice local | cohort |
| RXRα null local | phenotype |
| RXRα null/RXRγ null local | phenotype |
| RXRβ local | gene |
| RXRβ null local | phenotype |
| RXRβ null/RXRγ null local | phenotype |
| RXRγ local | gene |
| RXRγ null local | phenotype |
| S-adenosylmethionine | drug |
| SAH | drug |
| SAM | drug |
| SAMe local | drug |
| serum amyloid A local | drug |
| Serum cholesterol level local | phenotype |
| Serum fatty acid local | phenotype |
| serum triglyceride levels local | phenotype |
| SIRT1 | gene |
| SIRT5 local | gene |
| Skeletal muscle | cohort |
| SLC10A1 local | gene |
| SREBF1 | gene |
| STAT3 | gene |
| Sv/129 mice local | cohort |
| thiazolidinediones | drug |
| tissue damage | phenotype |
| Tlr4 | gene |
| TNF | gene |
| TNF-α | drug |
| total cholesterol | phenotype |
| triglyceride levels | phenotype |
| troglitazone local | drug |
| Trp53 | gene |
| type 2 diabetes | phenotype |
| unchanged insulin level local | phenotype |
| unchanged insulin sensitivity local | phenotype |
| Very-long chain acyl CoA dehydrogenase local | gene |
| Vitamin A | drug |
| Vitamin A depletion local | phenotype |
| vitamin B12 | drug |
| Vitamin E local | drug |
| VLDL local | drug |
| Wild-type animals local | cohort |
| wild-type mice | cohort |
| Wy-14,643 | drug |
| XPO1 local | gene |
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Multi-omics integration analysis identifies novel genes for alcoholism with potential overlap with neurodegenerative diseases. | 2021 | 34417470 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| The emerging role of FGF21 in alcohol consumption and dependence: mechanisms and therapeutic prospects. | Kaur S et al. | — | 2026 | → |
| Acetylation of proximal cysteine-lysine pairs by alcohol metabolism. | McGinnis CD et al. | — | 2025 | → |
| [Elucidating the Mechanisms of Lipid Accumulation in the Liver and Evaluating Potential Drug Targets]. | Koga T | — | 2025 | → |
| Single-nucleus multiomic analysis of Beckwith-Wiedemann syndrome liver reveals PPARA signaling enrichment and metabolic dysfunction. | Nirgude S et al. | — | 2025 | → |
| Single-nucleus multiomic analysis of Beckwith-Wiedemann syndrome liver reveals PPARA signaling enrichment and metabolic dysfunction | Nirgude S et al. | — | 2024 | — |
| Class III Alcohol Dehydrogenase Plays a Key Role in the Onset of Alcohol-Related/-Associated Liver Disease as an S-Nitrosoglutathione Reductase in Mice. | Haseba T et al. | — | 2023 | → |
| Dysfunction of liver-gut axis in marine medaka exposed to hypoxia and perfluorobutanesulfonate. | Li J et al. | — | 2023 | → |
| Total saponins from Panax japonicus attenuate acute alcoholic liver oxidative stress and hepatosteatosis by p62-related Nrf2 pathway and AMPK-ACC/PPARα axis in vivo and in vitro. | Qiu L et al. | — | 2023 | → |
| Oxidative Stress Causes Masculinization of Genetically Female Medaka Without Elevating Cortisol. | Mukai K et al. | — | 2022 | → |
| Phosphoproteomics identifies pathways underlying the role of receptor-interaction protein kinase 3 in alcohol-associated liver disease and uncovers apoptosis signal-regulating kinase 1 as a target. | Singh V et al. | — | 2022 | → |
| The Integrated "Multiomics" Landscape at Peak Injury and Resolution From Alcohol-Associated Liver Disease. | Das S et al. | — | 2022 | → |
| Multi-omics integration analysis identifies novel genes for alcoholism with potential overlap with neurodegenerative diseases. | Kapoor M et al. | — | 2021 | → |
| COUP-TFII in Health and Disease. | Polvani S et al. | — | 2019 | → |
| Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway. | La Paglia L et al. | — | 2017 | → |
| Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. | Polvani S et al. | — | 2016 | → |
| Protective Effect of PPAR<i>γ</i> Agonists on Cerebellar Tissues Oxidative Damage in Hypothyroid Rats. | Baghcheghi Y et al. | — | 2016 | → |
| Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor α protects against alcoholic liver disease. | Li HH et al. | — | 2014 | → |
| Nuclear receptors and pathogenesis of pancreatic cancer. | Polvani S et al. | — | 2014 | → |
| Peroxisome proliferator-activated receptor α, a potential therapeutic target for alcoholic liver disease. | Nan YM et al. | — | 2014 | → |
| The functional role of microRNAs in alcoholic liver injury. | McDaniel K et al. | — | 2014 | → |
| Effects of soy protein on alcoholic liver disease in rats undergoing ethanol withdrawal. | Yang HY et al. | — | 2012 | → |
| Lipidic last breath of life in patients with alcoholic liver disease. | Raszeja-Wyszomirska J et al. | — | 2012 | → |
| PPARγ and Oxidative Stress: Con(β) Catenating NRF2 and FOXO. | Polvani S et al. | — | 2012 | → |
| Retinoic acid synthesis and functions in early embryonic development. | Kam RK et al. | — | 2012 | → |
| Retinoid chemistry: synthesis and application for metabolic disease. | Curley RW | — | 2012 | → |
| Transcriptome analysis of garlic-induced hepatoprotection against alcoholic fatty liver. | Raghu R et al. | — | 2012 | → |
| Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. | Wu C et al. | — | 2011 | → |
| Long-term ethanol consumption promotes hepatic tumorigenesis but impairs normal hepatocyte proliferation in rats. | Chavez PR et al. | — | 2011 | → |
| Alcoholic liver disease and the gut-liver axis. | Szabo G et al. | — | 2010 | → |
| Alcohol-induced exacerbation of ischemic brain injury: role of NAD(P)H oxidase. | Zhao H et al. | — | 2010 | → |
| Chronic alcohol intake upregulates hepatic expression of carotenoid cleavage enzymes and PPAR in rats. | Luvizotto RA et al. | — | 2010 | → |